Investigation of miRNA expression profiles using cohort samples reveals potential early detectability of colorectal cancers by serum miR‑26a‑5p before clinical diagnosis

Hishida,Asahi; Yamada,Hiroya; Ando,Yoshitaka; Okugawa,Yoshinaga; Shiozawa,Manabu; Miyagi,Yohei; Daigo,Yataro; Toiyama,Yuji; Shirai,Yumiko; Tanaka,Koji; Kubo,Yoko; Okada,Rieko; Nagayoshi,Mako; Tamura,Takashi; Mori,Atsuyoshi; Kondo,Takaaki; Hamajima,Nobuyuki; Takeuchi,Kenji; Wakai,Kenji

doi:10.3892/ol.2022.13207

Investigation of miRNA expression profiles using cohort samples reveals potential early detectability of colorectal cancers by serum miR‑26a‑5p before clinical diagnosis

Authors:
- Asahi Hishida
- Hiroya Yamada
- Yoshitaka Ando
- Yoshinaga Okugawa
- Manabu Shiozawa
- Yohei Miyagi
- Yataro Daigo
- Yuji Toiyama
- Yumiko Shirai
- Koji Tanaka
- Yoko Kubo
- Rieko Okada
- Mako Nagayoshi
- Takashi Tamura
- Atsuyoshi Mori
- Takaaki Kondo
- Nobuyuki Hamajima
- Kenji Takeuchi
- Kenji Wakai
View Affiliations

Affiliations: Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466‑8550, Japan, Department of Hygiene, Fujita Health University School of Medical Sciences, Toyoake, Aichi 470‑1192, Japan, Department of Informative Clinical Medicine, Fujita Health University School of Medical Sciences, Toyoake, Aichi 470‑1192, Japan, Department of Genomic Medicine, Mie University Graduate School of Medicine, Tsu, Mie 514‑8507, Japan, Department of Gastrointestinal Surgery, Kanagawa Cancer Center Hospital, Yokohama, Kanagawa 241‑8515, Japan, Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa 241‑8515, Japan, Center for Antibody and Vaccine Therapy, Institute of Medical Science, Research Hospital, The University of Tokyo, Tokyo 108‑8639, Japan, Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Tsu, Mie 514‑8507, Japan, Department of Nutrition, Iga City General Hospital, Iga, Mie 518‑0823, Japan, Department of Surgery, Iga City General Hospital, Iga, Mie 518‑0823, Japan, Seirei Preventive Health Care Center, Hamamatsu, Shizuoka 433‑8558, Japan, Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466‑8550, Japan, Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466‑8550, Japan
Published online on: January 21, 2022 https://doi.org/10.3892/ol.2022.13207
Article Number: 87
Copyright: © Hishida et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have investigated the usefulness of microRNA (miRNA/miR) expression data for the early detection of colorectal cancer (CRC). However, limited data are available regarding miRNAs that detect CRC before clinical diagnoses. Accordingly, the present study investigated the early detectability of CRC by miRNAs using the preserved serum samples of the cohort participants affected with CRC within 2 years of study enrollment. First, the significant miRNAs were revealed using clinical CRC samples for a (seven early CRCs and seven controls) microarray analysis based on significance analysis of microarrays. Next, replicability was verified by reverse transcription‑quantitative (RT‑q)PCR (eight early CRCs and eight controls, together with 12 CRCs and 12 controls). Finally, early detectability was tested using the cohort samples of Japan Multi‑Institutional Collaborative Cohort Study (17 CRCs and 17 controls) to reveal how a certain number of patients developed CRC within 2 years after participation. In the discovery phase, miRNA expression measurements were conducted using a 3D‑Gene Human miRNA Oligo Chip for 2,555 miRNAs, and RT‑qPCR analyses were performed to validate the replicability. In the first validation set with eight CRCs with early clinical stage and eight age‑ and gender‑matched controls, miR‑26a‑5p and miR‑223‑3p demonstrated the highest diagnostic accuracy of area under the curve (AUC)=1.000 (sensitivity and specificity 100%). In an examination of the predictability of CRC incidence using pre‑clinical cohort samples, miR‑26a‑5p demonstrated good predictability of advanced CRC incidence with an AUC of 0.840. Overall, the present study revealed serum miR‑26a‑5p as a potential early detection marker for CRC.

View Figures

View References

1	Onyoh EF, Hsu WF, Chang LC, Lee YC, Wu MS and Chiu HM: The rise of colorectal cancer in Asia: Epidemiology, screening, and management. Curr Gastroenterol Rep. 21:362019. View Article : Google Scholar : PubMed/NCBI
2	Akimoto N, Ugai T, Zhong R, Hamada T, Fujiyoshi K, Giannakis M, Wu K, Cao Y, Ng K and Ogino S: Rising incidence of early-onset colorectal cancer-a call to action. Nat Rev Clin Oncol. 18:230–243. 2021. View Article : Google Scholar : PubMed/NCBI
3	Moore MA, Sobue T, Kuriki K, Tajima K, Tokudome S and Kono S: Comparison of Japanese, American-Whites and African-Americans-pointers to risk factors to underlying distribution of tumours in the colorectum. Asian Pac J Cancer Prev. 6:412–419. 2005.PubMed/NCBI
4	Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, et al: Japanese society for cancer of the colon and rectum. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 25:1–42. 2020. View Article : Google Scholar : PubMed/NCBI
5	Goodall GJ and Wickramasinghe VO: RNA in cancer. Nat Rev Cancer. 21:22–36. 2021. View Article : Google Scholar : PubMed/NCBI
6	Abe S, Matsuzaki J, Sudo K, Oda I, Katai H, Kato K, Takizawa S, Sakamoto H, Takeshita F, Niida S, et al: A novel combination of serum microRNAs for the detection of early gastric cancer. Gastric Cancer. 24:835–843. 2021. View Article : Google Scholar : PubMed/NCBI
7	Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda T, et al: Integrated extracellular microRNA profiling for ovarian cancer screening. Nat Commun. 9:43192018. View Article : Google Scholar : PubMed/NCBI
8	Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, Ono M, Takeshita F, Niida S, Shimizu C, et al: Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci. 107:326–334. 2016. View Article : Google Scholar : PubMed/NCBI
9	Yamada A, Horimatsu T, Okugawa Y, Nishida N, Honjo H, Ida H, Kou T, Kusaka T, Sasaki Y, Yagi M, et al: Serum miR-21-5p, miR-29a, and miR-125b are promising biomarkers for the early detection of colorectal neoplasia. Clin Cancer Res. 21:4234–4242. 2015. View Article : Google Scholar : PubMed/NCBI
10	Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A: Serum miR-21-5p as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 105:849–859. 2013. View Article : Google Scholar : PubMed/NCBI
11	Toiyama Y, Okugawa Y, Fleshman J, Boland CR and Goel A: MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: A systematic review. Biochim Biophys Acta Rev Cancer. 1870:274–282. 2018. View Article : Google Scholar : PubMed/NCBI
12	Takeuchi K, Naito M, Kawai S, et al: Study profile of the Japan multi-institutional collaborative cohort (J-MICC) study. J Epidemiol. 31:660–668. 2021. View Article : Google Scholar : PubMed/NCBI
13	Tusher VG, Tibshirani R and Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 98:5116–5121. 2001. View Article : Google Scholar : PubMed/NCBI
14	Asai Y, Naito M, Suzuki M, Tomoda A, Kuwabara M, Fukada Y, Okamoto A, Oishi S, Ikeda K, Nakamura T, et al: Baseline data of Shizuoka area in the Japan multi-institutional collaborative cohort study (J-MICC Study). Nagoya J Med Sci. 71:137–144. 2009.PubMed/NCBI
15	Morita E, Hamajima N, Hishida A, Aoyama K, Okada R, Kawai S, Tomita K, Kuriki S, Tamura T, Naito M, et al: Study profile on baseline survey of Daiko Study in the Japan multi-institutional collaborative cohort study (J-MICC Study). Nagoya J Med Sci. 73:187–195. 2011.PubMed/NCBI
16	Schwarzenbach H, da Silva AM, Calin G and Pantel K: Data normalization strategies for MicroRNA quantification. Clin Chem. 61:1333–1342. 2015. View Article : Google Scholar : PubMed/NCBI
17	Xie B, Ding Q, Han H and Wu D: miRCancer: A microRNA-cancer association database constructed by text mining on literature. Bioinformatics. 29:638–644. 2013. View Article : Google Scholar : PubMed/NCBI
18	Storey JD: The positive false discovery rate: A Bayesian interpretation and the q-value. Ann. Statist. 31:2013–2035. 2003. View Article : Google Scholar
19	Coronel-Hernández J, López-Urrutia E, Contreras-Romero C, Delgado-Waldo I, Figueroa-González G, Campos-Parra AD, Salgado-García R, Martínez-Gutierrez A, Rodríguez-Morales M, Jacobo-Herrera N, et al: Cell migration and proliferation are regulated by miR-26a-5p in colorectal cancer via the PTEN-AKT axis. Cancer Cell Int. 19:802019. View Article : Google Scholar : PubMed/NCBI
20	López-Urrutia E, Coronel-Hernández J, García-Castillo V, Contreras-Romero C, Martínez-Gutierrez A, Estrada-Galicia D, Terrazas LI, López-Camarillo C, Maldonado-Martínez H, Jacobo-Herrera N and Pérez-Plasencia C: MiR-26a downregulates retinoblastoma in colorectal cancer. Tumour Biol. Apr 26–2017.(Epub ahead of print). doi: 10.1177/1010428317695945. View Article : Google Scholar : PubMed/NCBI
21	Chai B, Guo Y, Cui X, Liu J, Suo Y, Dou Z and Li N: MiR-223-3p promotes the proliferation, invasion and migration of colon cancer cells by negative regulating PRDM1. Am J Transl Res. 11:4516–4523. 2019.PubMed/NCBI
22	Okugawa Y, Yao L, Toiyama Y, Yamamoto A, Shigemori T, Yin C, Omura Y, Ide S, Kitajima T, Shimura T, et al: Prognostic impact of sarcopenia and its correlation with circulating miR-21 in colorectal cancer patients. Oncol Rep. 39:1555–1564. 2018.PubMed/NCBI
23	Suzuki HI, Young RA and Sharp PA: Super-enhancer-mediated RNA processing revealed by integrative MicroRNA network analysis. Cell. 168:1000–1014.e15. 2017. View Article : Google Scholar : PubMed/NCBI
24	Asakura K, Kadota T, Matsuzaki J, Yoshida Y, Yamamoto Y, Nakagawa K, Takizawa S, Aoki Y, Nakamura E, Miura J, et al: A miRNA-based diagnostic model predicts resectable lung cancer in humans with high accuracy. Commun Biol. 3:1342020. View Article : Google Scholar : PubMed/NCBI
25	Yamada H, Suzuki K, Fujii R, Kawado M, Hashimoto S, Watanabe Y, Iso H, Fujino Y, Wakai K and Tamakoshi A: Circulating miR-21-5p, miR-29a, and miR-126 are associated with premature death risk due to cancer and cardiovascular disease: The JACC study. Sci Rep. 11:52982021. View Article : Google Scholar : PubMed/NCBI
26	Balzano F, Deiana M, Giudici SD, Oggiano A, Baralla A, Pasella S, Mannu A, Pescatori M, Porcu B, Fanciulli G, et al: miRNA stability in frozen plasma samples. Molecules. 20:19030–19040. 2015. View Article : Google Scholar : PubMed/NCBI
27	Wang K, Yuan Y, Cho JH, McClarty S, Baxter D and Galas DJ: Comparing the MicroRNA spectrum between serum and plasma. PLoS One. 7:e415612012. View Article : Google Scholar : PubMed/NCBI
28	Barrera-Ramirez J, Lavoie JR, Maganti HB, Stanford WL, Ito C, Sabloff M, Brand M, Rosu-Myles M, Le Y, Allan DS, et al: Micro-RNA profiling of exosomes from marrow-derived mesenchymal stromal cells in patients with acute myeloid leukemia: Implications in leukemogenesis. Stem Cell Rev Rep. 13:817–825. 2017. View Article : Google Scholar : PubMed/NCBI
29	Wang H, Hu Z and Chen L: Enhanced plasma miR-26a-5p promotes the progression of bladder cancer via targeting PTEN. Oncol Lett. 16:4223–4228. 2018.PubMed/NCBI
30	Miyamoto K, Seki N, Matsushita R, Yonemori M, Yoshino H, Nakagawa M and Enokida H: Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer. Br J Cancer. 115:354–363. 2016. View Article : Google Scholar : PubMed/NCBI
31	Ye MF, Lin D, Li WJ, Xu HP and Zhang J: MiR-26a-5p serves as an oncogenic MicroRNA in non-small cell lung cancer by targeting FAF1. Cancer Manag Res. 12:7131–7142. 2020. View Article : Google Scholar : PubMed/NCBI
32	Huang ZM, Ge HF, Yang CC, Cai Y, Chen Z, Tian WZ and Tao JL: MicroRNA-26a-5p inhibits breast cancer cell growth by suppressing RNF6 expression. Kaohsiung J Med Sci. 35:467–473. 2019.PubMed/NCBI